Calamos Advisors LLC Purchases 12,688 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Calamos Advisors LLC grew its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating) by 165.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 20,349 shares of the medical device company’s stock after purchasing an additional 12,688 shares during the period. Calamos Advisors LLC’s holdings in Tandem Diabetes Care were worth $2,366,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in shares of Tandem Diabetes Care by 11.6% during the fourth quarter. BlackRock Inc. now owns 6,478,638 shares of the medical device company’s stock valued at $975,164,000 after purchasing an additional 672,004 shares during the last quarter. Capital World Investors lifted its holdings in shares of Tandem Diabetes Care by 4.0% during the fourth quarter. Capital World Investors now owns 3,427,129 shares of the medical device company’s stock valued at $515,851,000 after purchasing an additional 133,133 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Tandem Diabetes Care by 11.8% during the fourth quarter. Invesco Ltd. now owns 1,942,971 shares of the medical device company’s stock valued at $292,456,000 after purchasing an additional 205,453 shares during the last quarter. State Street Corp lifted its holdings in shares of Tandem Diabetes Care by 2.2% during the fourth quarter. State Street Corp now owns 1,648,252 shares of the medical device company’s stock valued at $248,095,000 after purchasing an additional 35,825 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Tandem Diabetes Care by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 823,798 shares of the medical device company’s stock valued at $123,998,000 after purchasing an additional 22,743 shares during the last quarter. 94.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TNDM has been the subject of several recent research reports. TheStreet lowered shares of Tandem Diabetes Care from a “c-” rating to a “d+” rating in a report on Monday, June 13th. Piper Sandler decreased their price objective on shares of Tandem Diabetes Care from $170.00 to $120.00 in a report on Thursday, May 5th. StockNews.com lowered shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a report on Friday, July 1st. Oppenheimer decreased their price objective on shares of Tandem Diabetes Care from $142.00 to $130.00 in a report on Thursday, May 5th. Finally, Citigroup decreased their price objective on shares of Tandem Diabetes Care from $155.00 to $130.00 in a report on Tuesday, May 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $143.00.

Tandem Diabetes Care Trading Down 1.3 %

NASDAQ:TNDM opened at $62.05 on Monday. The company has a current ratio of 6.21, a quick ratio of 5.60 and a debt-to-equity ratio of 0.64. Tandem Diabetes Care, Inc. has a 12 month low of $52.08 and a 12 month high of $155.86. The company has a market cap of $3.97 billion, a PE ratio of 775.72 and a beta of 0.77. The company has a 50 day simple moving average of $62.17 and a two-hundred day simple moving average of $93.87.

Tandem Diabetes Care (NASDAQ:TNDMGet Rating) last posted its earnings results on Wednesday, May 4th. The medical device company reported ($0.23) EPS for the quarter. Tandem Diabetes Care had a return on equity of 1.64% and a net margin of 0.80%. The company had revenue of $175.91 million during the quarter, compared to the consensus estimate of $168.21 million. During the same period last year, the firm posted ($0.07) EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Research analysts forecast that Tandem Diabetes Care, Inc. will post 0.35 earnings per share for the current year.

Insider Activity

In other news, Director Christopher J. Twomey sold 248 shares of the business’s stock in a transaction on Thursday, May 5th. The shares were sold at an average price of $111.73, for a total transaction of $27,709.04. Following the completion of the sale, the director now owns 5,112 shares of the company’s stock, valued at approximately $571,163.76. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Rebecca B. Robertson sold 1,500 shares of the business’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $96.73, for a total transaction of $145,095.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Twomey sold 248 shares of the company’s stock in a transaction on Thursday, May 5th. The stock was sold at an average price of $111.73, for a total transaction of $27,709.04. Following the completion of the transaction, the director now directly owns 5,112 shares of the company’s stock, valued at approximately $571,163.76. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 5,000 shares of company stock valued at $361,270 and sold 22,607 shares valued at $1,829,208. Insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Profile

(Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.